Liraglutide

Evidence in perspective

The named U.S. product label is the appropriate source for its approved use, contraindications and handling. VICTOZA subcutaneous liraglutide: elimination half-life is approximately 13 hours; peak concentration occurs at 8–12 hours. Pediatric type 2 diabetes exposure was assessed from age 10; impaired-organ and pregnancy decisions require the complete label. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.

Who was studied

The population specified by this product label; other indications and jurisdictions remain outside this check.

What the sources found

Type 2 diabetes from age 10; specified cardiovascular-risk reduction in adults with established cardiovascular disease.

Regulatory scope

U.S. label record for NDA022341. This does not confer authorization on other products using the ingredient name.

What remains unknown

Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.

How it works

VICTOZA liraglutide 6 mg/mL prefilled pen

Consult the product label for pharmacology. A mechanism does not extend its approved indications.

Approved product exists

Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.

Understanding the evidence

Reported adverse effects

• Boxed thyroid C-cell tumor warning; contraindicated with personal/family medullary thyroid carcinoma or MEN2.

Named U.S. presentation only; selected label sections.

Source · Warnings and precautions / boxed warning